MicuRx Pharmaceuticals Inc.’s latest financing exercise – a Series C financing - brought it $55m which the Sino-US drug developer will use to progress its lead drug candidate, MRX-I, an oral oxazolidinone antibiotic currently in Phase III China trials.
MicuRx touts MRX-I’s oral availability and safety profile as advantages over the other drugs. MRX-I is designed to treat infections...